Alamar Biosciences, Inc.

Alamar Biosciences, Inc. (NASDAQ: ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $29.89, for a total value of $3,327,145.57. Following the sale, the insider directly owned 158,967 shares of

Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the following investor conferences:

Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences NASDAQ: ALMR reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program, or TAP, services quarter to date. The precision proteomics company also raised its full-year revenue outlook and highlighted newly announced large-scale collaborations with UK Biobank and GSK.

While the top- and bottom-line numbers for Alamar (ALMR) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK)  that will use Alamar's NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and a…

Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson's disease, Alzheimer's disease and other neurodegenerative conditions including rare dementias Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson's disease, Alzheimer's disease and other neurodegen…

FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX: NHLTY, NGHLF) today announced the launch of the UK Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disease.

Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations

Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total revenue. Gross margin improved to 60% on manufacturing efficiencies and consumables mix, but high operating expenses maintain losses amid aggressive investment.

Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.

Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring …

Alamar Biosciences (NASDAQ: ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering. Chief Executive Officer Yuling Luo said the quarter reflected continued adoption of the company's precision

Alamar Biosciences Inc. (NASDAQ:ALMR) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures.

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript